Adverum_Primary_Medium.png
Adverum Biotechnologies to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
September 08, 2022 16:05 ET | Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum_Primary_Medium.png
Adverum to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase
August 26, 2022 16:05 ET | Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum_Primary_Medium.png
Adverum Biotechnologies Reports Second Quarter 2022 Financial Results
August 11, 2022 16:05 ET | Adverum Biotechnologies, Inc.
- Dosing first Phase 2 LUNA trial participant with ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) on track for the third quarter of 2022 and preliminary data anticipated...
Adverum_Primary_Medium.png
Adverum Biotechnologies to Participate in the 2nd Annual H.C. Wainwright Ophthalmology Virtual Conference
August 10, 2022 16:05 ET | Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum_Primary_Medium.png
Adverum Biotechnologies Presents Best-Corrected Visual Acuity and Central Subfield Thickness Analyses After a Single IVT Injection of ADVM-022 (Ixo-vec) in the OPTIC Study in Wet AMD
July 15, 2022 08:32 ET | Adverum Biotechnologies, Inc.
- Study participants had an 81%-98% reduction in annualized anti-VEGF injections and demonstrated continuous aflibercept expression levels through three years - Mean best-corrected visual acuity...
Adverum_Primary_Medium.png
Adverum Biotechnologies Announces Upcoming Data Presentation at ASRS 2022
July 08, 2022 08:00 ET | Adverum Biotechnologies, Inc.
- Adverum to present new best-corrected visual acuity (BCVA) data from the OPTIC Trial of ADVM-022 (ixoberogene soroparvovec) in wet AMD REDWOOD CITY, Calif., July 08, 2022 (GLOBE NEWSWIRE)...
Adverum_Primary_Medium.png
Adverum Biotechnologies Completes IND Amendment and Prepares to Initiate the Phase 2 LUNA Trial of ADVM-022 in Wet AMD
July 06, 2022 16:05 ET | Adverum Biotechnologies, Inc.
- Cash runway extended into 2025 due to corporate restructuring to prioritize the clinical development of ADVM-022 and provide additional resources beyond anticipated one-year topline results of the...
Adverum_Primary_Medium.png
Adverum Biotechnologies Granted Priority Medicines (PRIME) Designation by European Medicines Agency for ADVM-022 in Wet AMD
June 24, 2022 08:00 ET | Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., June 24, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Adverum_Primary_Medium.png
Adverum Biotechnologies Presents Three-Year Aflibercept Protein Expression and Improvement in Anatomic Outcomes After a Single IVT Injection of ADVM-022 in the OPTIC Study in Wet AMD
June 09, 2022 08:00 ET | Adverum Biotechnologies, Inc.
- Three-year aflibercept protein expression demonstrates continuous and consistent therapeutic levels from ADVM-022 in OPTIC study subjects with wet age-related macular degeneration (wet AMD) - New...
Adverum_Primary_Medium.png
Adverum Biotechnologies Announces New Data at the Macula Society’s 2022 Annual Meeting
June 02, 2022 16:05 ET | Adverum Biotechnologies, Inc.
- OPTIC study of intravitreal gene therapy with ADVM-022 (AAV.7m8-aflibercept) for wet AMD shows therapeutic levels of aflibercept out to three years- New evaluation of the impact of baseline levels...